Axel Grothey

37.2k total citations · 13 hit papers
331 papers, 18.6k citations indexed

About

Axel Grothey is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Axel Grothey has authored 331 papers receiving a total of 18.6k indexed citations (citations by other indexed papers that have themselves been cited), including 282 papers in Oncology, 139 papers in Pulmonary and Respiratory Medicine and 77 papers in Pathology and Forensic Medicine. Recurrent topics in Axel Grothey's work include Colorectal Cancer Treatments and Studies (250 papers), Cancer Treatment and Pharmacology (104 papers) and Gastric Cancer Management and Outcomes (85 papers). Axel Grothey is often cited by papers focused on Colorectal Cancer Treatments and Studies (250 papers), Cancer Treatment and Pharmacology (104 papers) and Gastric Cancer Management and Outcomes (85 papers). Axel Grothey collaborates with scholars based in United States, Italy and Japan. Axel Grothey's co-authors include Daniel J. Sargent, Richard M. Goldberg, Takayuki Yoshino, Josep Tabernero, Eric Van Cutsem, Thierry André, Steven R. Alberts, Scott Kopetz, Aimery de Gramont and Charles L. Loprinzi and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Axel Grothey

323 papers receiving 18.2k citations

Hit Papers

Regorafenib monotherapy for previously treated metastatic... 2005 2026 2012 2019 2012 2010 2009 2015 2019 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
    2012 2.1k citations Axel Grothey, Eric Van Cutsem et al. profile →
  2. Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
    2010 1.1k citations Daniel J. Sargent, Silvia Marsoni et al. Journal of Clinical Oncology profile →
  3. Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy
    2009 1.0k citations Scott Kopetz, Daniel J. Sargent et al. Journal of Clinical Oncology profile →
  4. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
    2015 652 citations Josep Tabernero, Takayuki Yoshino et al. profile →
  5. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
    2019 594 citations Axel Grothey et al. profile →
  6. Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials
    2005 520 citations Daniel J. Sargent, Marc Buyse et al. Journal of Clinical Oncology profile →
  7. Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
    2008 519 citations Axel Grothey, Wei Dong et al. Journal of Clinical Oncology profile →
  8. A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group
    2020 468 citations Axel Grothey et al. profile →
  9. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database
    2016 434 citations Qian Shi, Richard Adams et al. profile →
  10. Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841
    2011 401 citations Qian Shi, Richard M. Goldberg et al. Journal of Clinical Oncology profile →
  11. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
    2021 331 citations Josep Tabernero, Axel Grothey et al. Journal of Clinical Oncology profile →
  12. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
    2019 284 citations Axel Grothey et al. profile →
  13. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
    2023 96 citations Takayuki Yoshino, Maria Di Bartolomeo et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Axel Grothey United States 57 14.2k 4.9k 3.9k 3.5k 3.3k 331 18.6k
Timothy Price Australia 48 10.7k 0.8× 5.0k 1.0× 3.1k 0.8× 2.8k 0.8× 1.9k 0.6× 476 14.8k
Takayuki Yoshino Japan 55 12.1k 0.9× 5.6k 1.2× 4.3k 1.1× 2.9k 0.8× 1.9k 0.6× 710 16.2k
Alfredo Falcone Italy 63 13.6k 1.0× 5.8k 1.2× 3.4k 0.9× 3.0k 0.9× 3.7k 1.1× 613 18.9k
Steven R. Alberts United States 60 12.4k 0.9× 5.2k 1.1× 3.0k 0.8× 4.6k 1.3× 3.3k 1.0× 311 17.1k
Aimery de Gramont France 64 20.1k 1.4× 6.8k 1.4× 4.4k 1.1× 5.3k 1.5× 4.7k 1.4× 333 25.0k
Michael J. Overman United States 58 11.2k 0.8× 3.9k 0.8× 4.1k 1.0× 3.9k 1.1× 2.3k 0.7× 447 16.5k
Christophe Louvet France 54 14.9k 1.0× 6.1k 1.3× 2.4k 0.6× 4.2k 1.2× 3.6k 1.1× 278 17.8k
Niall C. Tebbutt Australia 48 9.3k 0.7× 4.4k 0.9× 2.6k 0.7× 3.0k 0.9× 1.7k 0.5× 255 12.8k
Cathy Eng United States 61 10.8k 0.8× 3.9k 0.8× 2.0k 0.5× 6.3k 1.8× 4.2k 1.3× 409 16.2k
Roberto Labianca Italy 65 15.4k 1.1× 5.8k 1.2× 5.2k 1.3× 4.5k 1.3× 1.5k 0.4× 323 21.9k

Countries citing papers authored by Axel Grothey

Since Specialization
Citations

This map shows the geographic impact of Axel Grothey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Axel Grothey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Axel Grothey more than expected).

Fields of papers citing papers by Axel Grothey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Axel Grothey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Axel Grothey. The network helps show where Axel Grothey may publish in the future.

Co-authorship network of co-authors of Axel Grothey

This figure shows the co-authorship network connecting the top 25 collaborators of Axel Grothey. A scholar is included among the top collaborators of Axel Grothey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Axel Grothey. Axel Grothey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Siena, Salvatore, Kanwal Raghav, Toshiki Masuishi, et al.. (2024). HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nature Communications. 15(1). 10213–10213. 15 indexed citations
2.
Tsimberidou, Apostolia M., Axel Grothey, Darren Sigal, et al.. (2024). Phase I–II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 94(6). 787–798. 1 indexed citations
3.
Cutsem, Eric Van, Julien Taı̈eb, Rona Yaeger, et al.. (2023). ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer. Journal of Clinical Oncology. 41(14). 2628–2637. 63 indexed citations
4.
Tabernero, Josep, Axel Grothey, Eric Van Cutsem, et al.. (2021). Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. Journal of Clinical Oncology. 39(4). 273–284. 331 indexed citations breakdown →
5.
6.
VanderWalde, Noam A., et al.. (2021). Evolution and Current Status of the Multidisciplinary Management of Locally Advanced Rectal Cancer. JCO Oncology Practice. 17(7). 383–402. 11 indexed citations
7.
Kasi, Pashtoon Murtaza, Sarah Sawyer, Michelle L. Munro, et al.. (2021). BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer. BMJ Open. 11(9). e047831–e047831. 33 indexed citations
8.
Abraham, Jim, Daniel Magee, Chiara Cremolini, et al.. (2020). Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. Clinical Cancer Research. 27(4). 1174–1183. 35 indexed citations
9.
Seeber, Andreas, Florian Kocher, Alberto Puccini, et al.. (2020). Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. ESMO Open. 5(6). e000942–e000942. 32 indexed citations
10.
Yeh, Kun‐Huei, Jayesh Desai, Timothy Price, et al.. (2020). 85MO Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study). Annals of Oncology. 31. S1276–S1276. 1 indexed citations
11.
12.
Stein, Matthew K., Joanne Xiu, Michael G. Martin, et al.. (2020). Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma. Journal of Surgical Oncology. 121(8). 1320–1328. 18 indexed citations
13.
Vanderwalde, Ari M., Axel Grothey, Daniel A. Vaena, et al.. (2020). Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting. Journal of Personalized Medicine. 10(4). 252–252. 16 indexed citations
14.
Grothey, Axel, Jean‐Yves Blay, Nick Pavlakis, Takayuki Yoshino, & Jordi Bruix. (2020). Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treatment Reviews. 86. 101993–101993. 82 indexed citations
15.
Schmoll, Hans‐Joachim, Dirk Arnold, Aimery de Gramont, et al.. (2018). MODUL—a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. Journal of Cancer Research and Clinical Oncology. 144(6). 1197–1204. 23 indexed citations
16.
Salem, Mohamed E., Alberto Puccini, Axel Grothey, et al.. (2018). Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. Molecular Cancer Research. 16(5). 805–812. 159 indexed citations
17.
Kuczynski, Elizabeth A., Daniel J. Sargent, Axel Grothey, & Robert S. Kerbel. (2013). Drug rechallenge and treatment beyond progression—implications for drug resistance. Nature Reviews Clinical Oncology. 10(10). 571–587. 218 indexed citations
18.
Sargent, Daniel J., Silvia Marsoni, Geneviève Monges, et al.. (2010). Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer. Journal of Clinical Oncology. 28(20). 3219–3226. 1114 indexed citations breakdown →
19.
Hubbard, Joleen M. & Axel Grothey. (2010). Antiangiogenesis agents in colorectal cancer. Current Opinion in Oncology. 22(4). 374–380. 26 indexed citations
20.
Kozloff, Mark, Jordan Berlin, Patrick J. Flynn, et al.. (2010). Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study. Oncology. 78(5-6). 329–339. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Timothy Price Breakdown of academic impact, for papers by Takayuki Yoshino Breakdown of academic impact, for papers by Alfredo Falcone Breakdown of academic impact, for papers by Steven R. Alberts Breakdown of academic impact, for papers by Aimery de Gramont Breakdown of academic impact, for papers by Michael J. Overman Breakdown of academic impact, for papers by Christophe Louvet Breakdown of academic impact, for papers by Niall C. Tebbutt Breakdown of academic impact, for papers by Cathy Eng Breakdown of academic impact, for papers by Roberto Labianca
Rankless by CCL
2026